Elevated levels of neurofilament light chain (Nfl) in CSF and plasma are one promising biomarker for symptomatic FTD patients that harbor mutations in GRN, C9orf72, or MAPT [58]. The gene discussed is NEFL; the disease is frontotemporal dementia.